Therapeutic approach to treat virus-induced lung failure for severe COVID-19 shows promise in clinical trial
A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery ...
Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study
Johnson & Johnson (NYSE: JNJ) today announced results from additional analyses of the Phase 2 DAHLIAS study highlighting improvement in key measures of disease activity and significant IgG reduction ...
Johns Hopkins Medicine55m
Drug Combination Prompts Immune Response in Some Resistant Pancreatic Cancers
In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...